Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Re-engineered p53 chimera with enhanced homo-oligomerization that maintains tumor suppressor activity.

Re-engineered p53 chimera with enhanced homo-oligomerization that maintains tumor suppressor activity. Mol Pharm. 2014 Jul 07; 11(7):2442-52.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.